Calliditas Therapeutics AB (publ) (0A5R.L)

103,58 +0,03 (+0,03%) Alla chiusura: 05:50PM BST

Calliditas Therapeutics AB (publ)

Kungsbron 1, D5
Stockholm 111 22
Sweden
46 84 11 30 05
https://www.calliditas.se

Settore/i: 
Settore: 
Impiegati a tempo pieno: 192

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Renee Aguiar-Lucander	Chief Executive Officer	8,99M	N/D	1962
Mr. Fredrik Johansson	Chief Financial Officer	N/D	N/D	1977
Dr. Johan Haggblad Ph.D.	Chief Scientific Officer	1,66M	N/D	1958
Mr. Brian Gorman	Group General Counsel	N/D	N/D	1976
Ms. Sandra Frithiof	Head of Human Resources	N/D	N/D	1975
Ms. Ann-Kristin Myde BSc	Head of Clinical Development & VP of Project Management	N/D	N/D	1955
Dr. Krassimir Mitchev	Head of Medical Affairs	N/D	N/D	1959
Dr. Richard S. Philipson M.D.	Chief Medical Officer	N/D	N/D	1964
Ms. Teona Johnson	Head of US Marketing	N/D	N/D	N/D
Mr. David Ferraro	Head of US Sales	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetes, solid tumors, and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Governance aziendale

L'ISS Governance QualityScore di Calliditas Therapeutics AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.